175 related articles for article (PubMed ID: 34439773)
1. The Impact of Lung Proteases on Snake-Derived Antimicrobial Peptides.
Creane SE; Carlile SR; Downey D; Weldon S; Dalton JP; Taggart CC
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439773
[TBL] [Abstract][Full Text] [Related]
2. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.
Guyot N; Butler MW; McNally P; Weldon S; Greene CM; Levine RL; O'Neill SJ; Taggart CC; McElvaney NG
J Biol Chem; 2008 Nov; 283(47):32377-85. PubMed ID: 18799464
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway.
Cosgrove S; Chotirmall SH; Greene CM; McElvaney NG
J Biol Chem; 2011 Mar; 286(9):7692-704. PubMed ID: 21193404
[TBL] [Abstract][Full Text] [Related]
4. Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis.
Forde E; Humphreys H; Greene CM; Fitzgerald-Hughes D; Devocelle M
Antimicrob Agents Chemother; 2014; 58(2):978-85. PubMed ID: 24277028
[TBL] [Abstract][Full Text] [Related]
5. Antipseudomonal and Immunomodulatory Properties of Esc Peptides: Promising Features for Treatment of Chronic Infectious Diseases and Inflammation.
Cappiello F; Carnicelli V; Casciaro B; Mangoni ML
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429882
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases.
Lecaille F; Lalmanach G; Andrault PM
Biochimie; 2016 Mar; 122():151-68. PubMed ID: 26341472
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil elastase (NE) and NE inhibitors: canonical and noncanonical functions in lung chronic inflammatory diseases (cystic fibrosis and chronic obstructive pulmonary disease).
Roghanian A; Sallenave JM
J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):125-44. PubMed ID: 18518838
[TBL] [Abstract][Full Text] [Related]
8. Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.
Forde É; Schütte A; Reeves E; Greene C; Humphreys H; Mall M; Fitzgerald-Hughes D; Devocelle M
Antimicrob Agents Chemother; 2016 May; 60(5):2813-21. PubMed ID: 26902766
[TBL] [Abstract][Full Text] [Related]
9. Proteases and cystic fibrosis.
Voynow JA; Fischer BM; Zheng S
Int J Biochem Cell Biol; 2008; 40(6-7):1238-45. PubMed ID: 18395488
[TBL] [Abstract][Full Text] [Related]
10. Elastase-Activated Antimicrobial Peptide for a Safer Pulmonary Treatment of Cystic Fibrosis Infections.
Degasperi M; Sgarra R; Mardirossian M; Pacor S; Maschio M; Scocchi M
Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326782
[TBL] [Abstract][Full Text] [Related]
11. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis.
Attucci S; Gauthier A; Korkmaz B; Delépine P; Martino MF; Saudubray F; Diot P; Gauthier F
J Pharmacol Exp Ther; 2006 Aug; 318(2):803-9. PubMed ID: 16627747
[TBL] [Abstract][Full Text] [Related]
12. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.
Payne JE; Dubois AV; Ingram RJ; Weldon S; Taggart CC; Elborn JS; Tunney MM
Int J Antimicrob Agents; 2017 Sep; 50(3):427-435. PubMed ID: 28666755
[TBL] [Abstract][Full Text] [Related]
13. 2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation.
Griffin KL; Fischer BM; Kummarapurugu AB; Zheng S; Kennedy TP; Rao NV; Foster WM; Voynow JA
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):684-9. PubMed ID: 24325600
[TBL] [Abstract][Full Text] [Related]
14. In-depth biological characterization of two black soldier fly anti-
Van Moll L; Wouters M; De Smet J; De Vooght L; Delputte P; Van Der Borght M; Cos P
mSphere; 2023 Oct; 8(5):e0045423. PubMed ID: 37800918
[TBL] [Abstract][Full Text] [Related]
15. Targeting defective pulmonary innate immunity - A new therapeutic option?
Belchamber KBR; Donnelly LE
Pharmacol Ther; 2020 May; 209():107500. PubMed ID: 32061706
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, antimicrobial activity and LPS-interaction properties of SB041, a novel dendrimeric peptide with antimicrobial properties.
Bruschi M; Pirri G; Giuliani A; Nicoletto SF; Baster I; Scorciapino MA; Casu M; Rinaldi AC
Peptides; 2010 Aug; 31(8):1459-67. PubMed ID: 20438783
[TBL] [Abstract][Full Text] [Related]
17. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V
Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772
[TBL] [Abstract][Full Text] [Related]
18. Induction of interleukin-8 release by lung epithelium with cystic fibrosis epithelial lining fluid is marginally affected by inhibitors of interleukin-1beta.
Coulter KR; Allen ED; Hart J; Wewers MD; Castile RG; Knoell DL
Pharmacotherapy; 2000 Jan; 20(1):64-74. PubMed ID: 10641976
[TBL] [Abstract][Full Text] [Related]
19. Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients.
Mauch RM; Hentschel J; Aanaes K; Barucha A; Nolasco da Silva MT; Levy CE; Høiby N; Mainz JG
Pediatr Pulmonol; 2020 Apr; 55(4):959-967. PubMed ID: 32022432
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis.
Moffitt KL; Martin SL; Jones AM; Webb AK; Cardwell C; Tunney MM; Elborn JS
J Cyst Fibros; 2014 Jan; 13(1):63-8. PubMed ID: 23860440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
